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Brain tumors, including the majority gliomas, are the leading cause of cancer-related death
in children. World Health Organization has divided pediatric brain tumors into different
grades and, based upon cDNAmicroarray data identifying gene expression proﬁles (GEPs),
it has become evident in the last decade that the various grades involve different types of
genetic alterations. However, it is not known whether ion channel and transporter genes,
intimately involved in brain functioning, are associated with such GEPs. We determined
the GEPs in an available cohort of 10 pediatric brain tumors initially by comparing the data
obtained from four primary tumor samples and corresponding short-term cultures. The
correspondence between the two types of samples was statistically signiﬁcant. We then
performed bioinformatic analyses on those samples (a total of nine) which corresponded to
tumors of glial origin, either tissues or cell cultures, depending on the best “RNA integrity
number.” We used R software to evaluate the genes which were differentially expressed
(DE) in gliomas compared with normal brain. Applying a p-value below 0.01 and fold change
≥4, led to identiﬁcation of 2284 DE genes.Through a Functional Annotation Analysis (FAA)
using the NIH-DAVID software, the DE genes turned out to be associated mainly with:
immune/inﬂammatory response, cell proliferation and survival, cell adhesion and motil-
ity, neuronal phenotype, and ion transport. We have shown that GEPs of pediatric brain
tumors can be studied using either primary tumor samples or short-term cultures with
similar results. From FAA, we concluded that, among DE genes, pediatric gliomas show a
strong deregulation of genes related to ion channels and transporters.
Keywords: pediatric gliomas, gene expression profiling, short term culture, ion channels and transporters, biological
processes
INTRODUCTION
Brain tumors are themost common solidmalignancy and the lead-
ing cause of cancer-related deaths in children (Pollack et al., 2006;
Dubuc et al., 2010). Among these cancers, gliomas represent the
vast majority, ranging from 56 to 70%, depending on the registry
and the histological criteria used (Qaddoumi et al., 2009). The
most common pediatric gliomas are astrocytomas and ependy-
momas. They are classiﬁed as low grade gliomas (LGGs) and high
grade gliomas (HGGs; Qaddoumi et al., 2009). According to the
World Health Organization (WHO), low grade astrocytomas and
ependymomas include pilocytic astrocytomas (PAs) WHO grade
I, subependymal giant cell astrocytomas (SEGAs) WHO grade
I, pleomorphic xantoastrocytomas (PXAs) WHO grade II, ﬁb-
rillary astrocytomas (FAs) WHO grade II, ependymomas WHO
grade II, subependymomas WHO grade I, and myxopapillary
ependymomas WHO grade I (Louis et al., 2007). On the other
hand, the high grade astrocytoma and ependymoma group is rep-
resentedmainly by anaplastic astrocytomas (AAs;WHOgrade III),
glioblastoma multiforme (GBM; WHO grade IV), and anaplastic
ependymomas WHO grade III. In the group of low grade ependy-
momas, we also included the newly identiﬁed angiocentric glioma
(AG), which is currently interpreted as predominantly juvenile
WHO grade I ependymoma. GBM and AA are more frequent in
adults (Qiu et al., 2008) and represent only 7% of all pediatric
brain tumors (Rickert et al., 2001). Despite aggressive surgical
resection and radiotherapy accompanied or followed by adjuvant
chemotherapy, pHGGs prognosis remains poor (Massimino et al.,
2010).
Gene mutations, copy number aberrations, structural
rearrangements, or deregulation of the transcriptome have been
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shown to contribute to the development of brain tumors and cur-
rently play an integral role in their classiﬁcation (Mischel et al.,
2004; Dubuc et al., 2010). Moreover, the deﬁnition of molecular
pathways differently expressed in brain tumors can help in identi-
fying putative therapeutic targets (Bredel et al., 2005; Faury et al.,
2007; Dubuc et al., 2010). Toward this aim, numerous recent stud-
ies, mainly on adults, have employed highly sensitive molecular
techniques, such as comparative genomic hybridization (Koschny
et al., 2002;Wiltshire et al., 2004) and cDNA microarrays (de Bont
et al., 2008; Dubuc et al., 2010). In particular, cDNA microarrays
are enabling evaluation of genome-wide gene expression proﬁles
(GEPs) of brain tumors. It has been shown that signiﬁcant mole-
cular heterogeneity exists within morphologically deﬁned cancers
(Rorive et al., 2006) and that the determination of GEPs in gliomas
strongly affects prediction of survival (Freije et al., 2004). Never-
theless, clinically relevant molecular signatures have been iden-
tiﬁed among brain tumors. From these studies, it has emerged
that LGGs are characterized by an “antimigratory gene proﬁle,”
which is progressively lost in HGGs (Rorive et al., 2006). The lat-
ter appear to be characterized more by deregulation of genetic
pathways belonging to DNA repair, transcriptional regulation, cell
division, cell proliferation, and survival (Vital et al., 2010). Inte-
grated molecular genetic proﬁling of pediatric HGGs revealed key
differences with adult HGGs (Paugh et al., 2010). Such molecular
differences can in turn affect prognosis (Faury et al., 2007).
Ion channels and transporters are increasingly considered to
bear pathophysiological relevance in tumor biology (Arcangeli
et al., 2009; Arcangeli and Yuan, 2011). Although these proteins
are inherent to brain (neuronal and glial) functioning and have
been shown to be dysregulated in brains tumors (Preussat et al.,
2003; Sontheimer, 2008; Cuddapah and Sontheimer, 2011; Arvind
et al., 2012), only a few studies have speciﬁcally studied the genes
encoding ion channels and transporters and their relevance in
pediatric gliomas. Such small number of studies is due to the low
incidence of the disease and the rarity of tissues appropriate for
molecular characterization (Rorive et al., 2006; Paugh et al., 2010;
Vital et al., 2010). Besides affecting the neoplastic progression, the
ion channel and transporter complement of glioma cells affects
how these cells alter the composition of the peritumor space, par-
ticularly the pH, [K+], and neurotransmitter levels. These factors
likely contribute to cause tumor-related epileptic seizures, a very
serious morbidity factor in brain cancer with a poorly understood
pathophysiology (Shamji et al., 2009).
On the whole the importance of obtaining a full picture of the
membrane transporter expression in brain cancer is clear.
In this study, we analyzed GEPs of a cohort of pediatric glioma
(mainly LGG) samples. Due to the limited quantity and hetero-
geneity of the biological material available, we ﬁrst conﬁrmed that
short-term culturing of the glioma samples would not alter their
GEPs, while allowing to obtain higher amounts and better quality
of RNA. Subsequent evaluation of differentially expressed (DE)
genes was based on Functional Annotation Analysis (FAA).
MATERIALS AND METHODS
TISSUE COLLECTION
Surgical specimens were obtained from the Neurosurgery Unit,
Meyer Children’s University Hospital, Firenze, Italy. Informed
consent for the data collection was obtained from the parents,
or the legal guardians. The study overall was approved by the
local international review board of the Hospital. From each fresh
surgical specimen a macroscopically representative fragment was
selected, that was further cut into two corresponding pieces. One
was further processed for histological analysis and diagnosis. An
expert pathologist, AMB, determined the histological diagnosis
using standard criteria (Buccoliero et al., 2002). The other piece
was further subdivided under sterile conditions. The two pieces
were immersed either in RNAlater™solution (Ambion by Life
Technologies, USA), for RNA extraction or in phosphate buffered
saline (PBS), until minced for obtaining the primary culture. The
cohort comprised ﬁve PAs (WHO grade 1), one AG (WHO grade
1), one ependymoma (E; WHO grade 2), one anaplastic oligoden-
droglioma (AO; WHO grade 3), one atypical meningioma (AM;
WHO grade 2), and 1 GBM (WHO grade 4; Table 1). The AM was
used only for the comparison of the GEPs of fresh tissue versus
cell culture.
PRIMARY CELL CULTURES
The surgical fragment collected and maintained in PBS under
sterile conditions was mechanically minced with sterile blades in
60mm Petri dishes (Euroclone Ltd, Celbio, Italy) and transferred
into 15ml tubes (SARSTEDT S.R.L., Italy) containing Dulbecco’s
Modiﬁed Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12,
Gibco-Invitrogen, Italy) and 0.25mg/ml of type II collagenase.
After incubating the minced tissue at 37˚C for 5min, cells were
pelletted and resuspended in complete medium: DMEM/F-12
supplemented with 10% fetal bovine serum (Sigma, Italy) and
antibiotics. Finally, the cell suspension was aliquoted into Petri
dishes and maintained at 37˚C in a humidiﬁed atmosphere con-
taining 5% CO2 in air. Medium was replaced, after washing twice
with PBS every 2 days, during the whole culture period (15 days
maximum). Cultures were used for RNA extraction no later than
2weeks following plating, to avoid over growth of mesenchymal
cells.
CDNA MICROARRAY: RNA EXTRACTION, LABELING, AND
HYBRIDIZATION
Total RNA was isolated by Trizol reagent according to the man-
ufacturer’s protocol (Invitrogen S.R.L, Italy). RNA integrity was
checked using the Agilent 2100 Bioanalyzer (Agilent Technolo-
gies Italia, Italy), evaluating the RNA integrity number (RIN)
of each sample (Schroeder et al., 2006). High quality quanti-
ﬁed RNA was puriﬁed on silica gel columns using the RNeasy
MinElute Cleanup kit (QIAGEN S.p.A., Italy). The quality of the
puriﬁed RNA was conﬁrmed by checking on a NanoDrop spec-
trophotometer ND-1000 (NanoDrop Technologies, Germany).
GEPs were determined using Agilent oligonucleotide microar-
ray by one-color technology. About 500 ng of total RNA were
used for each sample to generate cDNA probes. cDNA syn-
thesis and labeling were performed by Agilent’s Quick Amp
Labeling Kit. Hybridization was performed on human whole
genome 44,000 oligonucleotide microarrays using reagents and
protocols provided by the manufacturer (Agilent Technolo-
gies, Manual Part Number G4140-90042). The Feature extrac-
tion software (Agilent, version 9.5), was used to quantify the
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Table 1 | Characteristics of tumor samples included in the study.
Patient
ID
Tumor
type
WHO
Grade
Location Sex Age (years) Seizure Fresh tissue
sample RIN
Primary
culture RIN
168 AM II Fronto-temporal region F 13 No 8.0 9.3
186 PA I Cerebellum M 7 No 7.7 9.2
192 PA I Cerebellum M 6 No 2.5 8.4
224 AO III Right rolandic region F 30 No 8.2 9.5
232 E II Right frontal region F 11 No 7.8 N/A
234 GBM IV Giant, left hemisphere F 8months No 6.9* 9.1
250 PA I Cerebellum F 11 No 6.2 N/A
1001 AG I Left parieto-occipital region F 10 Yes 2.4 9.0
0102 PA I Cerebellum M 20 No 2.2 9.5
1002 PA I Cerebellum M 10 No 7.3 8.1
All the samples included in the study are reported. AO (sample 224), PA (sample 186), AM (sample 168), and PA (sample 1001) were used for the GEP comparison
between fresh tissue samples and their derived primary cultures (see Figure 1). The other analysis referred to glioma cohort were carried out only on samples with
the best RIN value (in bold) and were performed in all the tumor types listed in theTable, excepted for the meningioma (AM, sample 168). Abbreviations: PA, pilocytic
astrocytoma; AO, anaplastic oligodendroglioma; GBM, glioblastoma multiforme; E, ependymoma; AM, atypical meningioma; AG, angiocentric glioma; F, female; M,
male; N/A, not available.
∗For the determination of GEP of GBM sample the fresh tissue was used in the bioinformatic analyses because, despite the best RIN value, the RNA obtained from
the short-term culture was not sufﬁcient to perform microarray experiment.
intensity of ﬂuorescent images. The FirstChoice® Human Brain
Reference RNA (Ambion, Applied Biosystems, Life Technolo-
gies Corporation, USA) was used as a reference. The Ambion®
FirstChoice® Human Brain Reference RNA is a high quality stan-
dard, suitable for human microarray analysis, pooled from dif-
ferent brain regions from 12 donors. The Reference RNA passes
the strict quality control criteria for purity and integrity used for
the MicroArray Quality Control (MAQC) project. FirstChoice®
Human Brain Reference RNA is the same RNA (identical manu-
facturing lot) used for the MAQC project (MAQC Consortium,
2006).
Statistical analysis of microarray data
Data analysis was performed using R software version 2.11.01 by
Bioconductor Packages2 using row images (dat ﬁles), as obtained
from the Feature extraction analysis (see above). Data were nor-
malized using “scale” normalization (Smyth and Speed, 2003) as
implemented in“limma”package,made available onBioconductor
(see text footnote 2).
Comparison between fresh samples and primary cultures
The log 2 normalized values were used to evaluate differences in
gene expression between fresh tissue samples and their derived
primary cultures. Four different brain tumor samples of dif-
ferent histological types (including a non-glial tumor, e.g., one
meningioma), and their corresponding short-term cultures, were
analyzed: PA (sample 186), AO (sample 224), AM (sample 168),
and PA (sample 1002). It is worth noting that when multiple
arrays are being compared to each other, the raw data from all
chips should be normalized together. A normalization between
arrays, like scale normalization, assumes a common distribution
1http://www.r-project.org/
2http://www.bioconductor.org/
for datasets. Our collection of samples is however heterogeneous,
as it combines different patients and distinct pathologies. As such,
it clearly displays a degree of intrinsic variability that should be
carefully evaluated.On theotherhand, in the following analysis,we
were mainly interested in detecting those biological patterns that
appear to be consistently altered in all recorded dataset, beyond
the speciﬁc peculiarities that make each sample inherently differ-
ent. Moreover, it can be argued that relatively few genes are DE
across the different experiments, an a priori ansatz that one can
subsequently validated. Inspired by this rationale, we proceeded
with the aforementioned normalization strategy and checked a
posteriori the correlation coefﬁcients among scrutinized dataset.
Interestingly, the correlation coefﬁcients between the expression
values obtained in the fresh tissue samples and the correspond-
ing measures relative to the cell culture resulted in: PA (sample
186), 0.88; AO, 0.86; AM, 0.94; and PA (sample 1002), 0.90. The
correlation coefﬁcients among all other dataset returned values
close to 0.8, so conﬁrming on the whole our former assumption.
In particular, cultured samples appear to preserve a large part
of the biological information as contained in their original fresh
homologs.
Analysis of DE genes
To perform the differential expression analysis, aimed to iden-
tify deregulated genes in gliomas, we considered the log 2 ratio
of intensity values of each gene, respect to the corresponding
intensity value in the control sample (normal brain). This analy-
sis was therefore applied to nine samples, either fresh or culture,
depending on the best RIN (see Table 1).
A One Sample t -test was applied to the log-ratios and a p-value
was calculated for each gene. A Bonferroni procedure was applied
to take into account the multiple testing correction. To pick out
the DE genes we considered a threshold of 0.01 on the corrected
p-value, plus an average cut off of fourfold changes.
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Functional annotation analysis
Functional annotation analysis was performed using NIH-DAVID
software (version6.7)3.Our aimwas toﬁnd themost relevantGene
Ontology (GO) terms associated with DE genes. For this purpose,
we used the parameter GOTERM_BP_FAT, and the signiﬁcance
p-value threshold was set<0.01, with Bonferroni multiple testing
correction.
RESULTS
EVALUATION OF DIFFERENCES IN GENE EXPRESSION BETWEEN FRESH
TISSUE SAMPLES AND THEIR DERIVED SHORT-TERM CULTURES
We ﬁrst analyzed the GEPs of four fresh pediatric brain tumor
samples of different histogenesis (see Materials and Methods) and
their corresponding short-term culture (15 days). Thus, we deter-
mined whether the establishment and short-term maintenance of
the cell culture would alter the GEP of the primary tissue sample.
In Figure 1, the (normalized) gene expression values associated
with the fresh tumor samples are plotted against the data obtained
from the corresponding short-term cultures. Clearly, the two sets
of data are positively correlated. This implied that the short-term
culturing preserved a large portion of the original GEPs. On the
other hand, and beyond the qualitative assessment, a dispersion
around the idealized linear distribution was apparent (Figure 1).
The latter observation reﬂected the inherent variability of the scru-
tinized samples,mainly due to the histopathological differences of
tumors analyzed. In order to evaluate the data quantitatively, we
calculated the correlation coefﬁcient values between fresh tissue
3http://david.abcc.ncifcrf.gov/
samples and the corresponding culture, applying the assumptions
and the procedure described in Section “Materials and Methods.”
The values thus obtained were: A: 0.88, B: 0.86, C: 0.94, and D:
0.90. Based on the above, we argued that cultured samples pre-
serve a substantial degree of similarity with their fresh analogs.
We concluded, therefore, that either primary tissue samples or
their corresponding short-term cultures, could be used to perform
cDNA microarray analyses. This allowed the use of either short-
term cultures or primary tissue samples depending on best RIN
value. On these bases, we performed cDNA microarray analyses of
DE genes in the available cohort of pediatric gliomas (Table 1).
ANALYSIS OF DIFFERENTIALLY EXPRESSED GENES OF GLIOMAS
COMPARED TO NORMAL BRAIN
We determined the GEPs of nine gliomas, mainly LGGs (PAs, AG,
AO, and E) and a GBM. Since the analysis mainly focused on
glial-derived tumor, the AM sample was omitted. The Ambion®
FirstChoice® Human Brain Reference RNA (Applied Biosystems,
Life Technologies Corporation, USA), which derives from the
pooling of 12 different donors and several brain regions, was
used as the normal control reference. Although the tumor ana-
lyzed had different sites of presentation, we used a “whole brain”
control sample, as previously described by Godard et al. (2003),
to ensure a reproducible, tissue-speciﬁc reference. The expres-
sion proﬁle of each gene was evaluated as detailed in Section
“Materials and Methods.” In particular, a gene was assumed to
be DE when the corrected p-value was lower than 0.01 and
the fold change was ≥4. We obtained 2284 probes matching
such requisites. The 2284 DE genes are shown in a cluster dia-
gram in Figure 2 and are listed in Table S1 in Supplementary
FIGURE 1 | Comparison of GEPs between fresh tissue samples and their
derived primary cultures.The log 2 normalized values for each gene of fresh
tissue pediatric brain tumors versus its primary culture are matched. In (A–D)
are represented PA (sample 186), AO (sample 224), AM (sample 168), and PA
(sample 1002) samples, respectively. The degree of similarity of each sample
respect to its primary culture has been quantitatively explored by calculating
the associated correlation coefﬁcients. Average Pearson’s correlation
coefﬁcients were: (A), 0.88; (B), 0.86; (C), 0.94, and (D), 0.90.
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FIGURE 2 | Heatmap of DE genes, performed, and plotted using
“heatmap.2” function in R. Samples and genes (columns and rows
respectively) are reordered on the basis of the average value of gene
expression (log 2 ratio), and give rise to groups of genes and samples with
similar average expression levels, according to the color key, shown on the
top.
Material. About 1219 out of the 2284 DE genes (53%) were
downregulated, whilst 1065 DE genes (47%) were upregulated
(Figure 2).
FUNCTIONAL ANNOTATION ANALYSIS OF THE GLIOMA SAMPLES
COHORT
We next performed FAA on the microarray data of DE genes,
based on GO terms enrichment, using the NIH-DAVID software.
It emerged that the DE genes are signiﬁcantly associated to 43
groups (called “terms”) of potential functional distinction (Table
S2 in Supplementary Material). This type of analysis (Huang et al.,
2009) identiﬁes the most altered biological processes, regardless
their up or down expression. Hence, we performed a second
FAA, taking into account separately those genes that are up or
downregulated.
Upregulated genes
The FAA on the DE genes that are overexpressed led to 61 enriched
terms (Table 2; Table S3 in Supplementary Material). The major-
ity of them belong to three main biological processes that can
be summarized as follows: immune/inﬂammatory response, cell
proliferation and survival, cellular adhesion and motility. Table 2
shows the upregulated terms divided into the threemain biological
processes identiﬁed. Some representative genes, with their median
expression values (reported as fold change), are also reported.
Downregulated genes
Functional annotation analysis of these genes instead revealed 12
terms. Appling the same criteria of selection as in the FAA of
upregulated genes, we found that they were mostly related to two
main biological processes: neuronal phenotype and ion transport
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Table 2 | Statistically significant biological processes, associated to the upregulated genes only, represented by DE GO terms in our cohort of
glioma samples.
Biological processes GO terms Representative genes Fold change
Immune/inﬂammatory response GO:0006955∼ immune response C1QA 2.25
GO:0009611∼ response to wounding ANXA1 3.61
GO:0006952∼defense response ANXA5 2.99
GO:0006954∼ inﬂammatory response CTGF 6.20
GO:0019882∼ antigen processing and presentation CD163 3.12
GO:0042060∼wound healing NOTCH2 2.21
GO:0048002∼ antigen processing and presentation of peptide antigen CD44 3.13
GO:0010033∼ response to organic substance STAT1 2.78
GO:0002684∼positive regulation of immune system process MYC 2.75
GO:0046649∼ lymphocyte activation COL1A1 6.72
GO:0002460∼ adaptive immune response based on somatic recom-
bination of immune receptors built from immunoglobulin superfamily
domains
IFI30 4.69
GO:0002250∼ adaptive immune response CDKN1A 2.26
GO:0042110∼T cell activation CDKN2A 2.91
GO:0045321∼ leukocyte activation ERBB2 2.48
GO:0002504∼ antigen processing and presentation of peptide or poly-
saccharide antigen via MHC class II
HBEGF 3.13
GO:0045087∼ innate immune response FN1 4.86
GO:0002694∼ regulation of leukocyte activation
GO:0002252∼ immune effector process
GO:0050778∼positive regulation of immune response
GO:0051249∼ regulation of lymphocyte activation
GO:0006968∼ cellular defense response
GO:0002449∼ lymphocyte mediated immunity
Cell proliferation and survival GO:0043067∼ regulation of programmed cell death KCNMA1 (variant 2) 2.53
GO:0042127∼ regulation of cell proliferation ANXA5 2.99
GO:0010941∼ regulation of cell death ANXA1 3.61
GO:0042981∼ regulation of apoptosis MMP9 6.35
GO:0043065∼positive regulation of apoptosis CD44 3.13
GO:0043068∼positive regulation of programmed cell death NOTCH2 2.21
GO:0010942∼positive regulation of cell death IFI30 4.69
GO:0006917∼ induction of apoptosis STAT1 2.78
GO:0012502∼ induction of programmed cell death MYC 2.75
GO:0008285∼negative regulation of cell proliferation CDKN1A 2.26
GO:0006915∼ apoptosis CDKN2A 2.91
GO:0008219∼ cell death ERBB2 2.48
GO:0008284∼positive regulation of cell proliferation HBEGF 3.13
GO:0016265∼death PIM1 2.76
GO:0012501∼programmed cell death
GO:0043066∼negative regulation of apoptosis
GO:0006916∼ anti-apoptosis
GO:0043069∼negative regulation of programmed cell death
GO:0060548∼negative regulation of cell death
Cellular adhesion and motility GO:0006928∼ cell motion ANXA1 3.61
GO:0016477∼ cell migration CTGF 6.20
GO:0051674∼ localization of cell CD44 3.13
GO:0048870∼ cell motility MMP9 6.35
GO:0007155∼ cell adhesion COL1A1 6.72
GO:0022610∼biological adhesion TGFBI 6.98
(Continued)
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Table 2 | Continued
Biological processes GO terms Representative genes Fold change
GO:0030198∼extracellular matrix organization ANXA2P1 4.99
GO:0051270∼ regulation of cell motion ANXA2 5.02
GO:0030334∼ regulation of cell migration ERBB2 2.48
GO:0006935∼ chemotaxis HBEGF 3.13
GO:0042330∼ taxis FN1 4.86
GO:0040012∼ regulation of locomotion
Some representative genes are reported with the relative fold change.
(Table 3; Table S4 in Supplementary Material). Table 3 shows
the downregulated terms divided into the two main biological
processes identiﬁed. Some representative genes, with their median
expression values (reported as fold change), are also reported.
ANALYSIS OF DE GENES ASSOCIATED TO THE TRANSPORTER
CLASSIFICATION DATABASE
To further deepen the studyof ion transport process,weperformed
a more focused analysis selecting, among the DE genes, the probes
associated to ion channels, and transporters according to the read-
ily available Transporter Classiﬁcation Database for ion channels
and transporters4.We thus identiﬁed 67 DE genes (Figure 3; Table
S5 in Supplementary Material). Such genes included two main
groups: those coding for transporters (n = 45; 67%) and those
coding for ion channels (n = 22; 33%). Most of these genes encode
solute carriers (SLC, n = 25), whereas other categories include
potassium channels (n = 16), ATPases (n = 8), ATP-binding cas-
settes (ABC, n = 7), calcium channels (n = 5), annexins (ANXA,
n = 4), and two sodium channel beta subunits. Thirty-three per-
centage of the 67 genes belonging to ion channels and transporters
are upregulated and they are mainly transporters. On the other
hand, among the downregulated genes, many (48%) belongs to
ion channel encoding genes.
DISCUSSION
We have applied a method, previously developed for adult gliomas
(Masi et al., 2005), to obtain short-term cultures of pediatric
gliomas. This method proved to be suitable for cDNA microar-
ray studies of pediatric brain tumors, where the availability of
fresh primary samples is limited by surgical procedures and diag-
nostic necessities, as well as possible ethical constraints. Moreover,
establishing tissue cultures providing a “pure” population of pro-
liferating tumor cells makes it unnecessary to selectively isolate
and capture malignant glial cells, for further analyses. Finally,
the primary culture samples we analyzed often showed better
RIN values (see Table 1), hence strongly inﬂuencing the deci-
sion whether to include or not a patient into a study. Indeed,
when we plotted and calculated the correlation coefﬁcients of
the gene expression values associated with the fresh tumor sam-
ples against the data obtained from the corresponding short-term
cultures, the two sets of data turned out to be positively cor-
related. This implied that the short-term culturing preserved a
4http://www.tcdb.org/hgnc_explore.php
large portion of the original GEPs. This method, when applied
routinely, could overcome possible molecular degradation and
contamination by non-cancerous cells (although some differen-
tiation or selection of unwanted cellular phenotypes could not be
ruled out), which often biases molecular studies in primary tumor
samples.
The short-term culture system allowed the molecular char-
acterization of the tumors, and could be extended to further
functional studies. In the present study we determined the GEPs
of nine gliomas (mainly LGGs/PAs), a small number of sam-
ples, although compatible to those reported in recent studies
(Wong et al., 2005; Faury et al., 2007; Kasuga et al., 2008).
Almost half of the DE genes were upregulated, while the others
were downregulated. The further FAA led us to identify terms
of the DE genes in our samples. Besides being obtained with
different biomolecular and analytical procedures, the genes we
identiﬁed as DE belonged to terms almost identical to those
reported in Wong et al. (2005) and Faury et al. (2007). This fur-
ther stress the validity of the methods we applied in the present
study.
In fact, that the terms comprising the overexpressed DE
genes were mainly those concerned with immune/inﬂammatory
response, control of proliferation/survival, and regulation of cell
adhesion and migration.
In particular, the genes belonging to the immune/inﬂammatory
response are represented by human leukocyte antigen (HLA, e.g.,
MHC) genes, mainly HLA-D genes. Since it is known that neu-
ronsundernormal conditions inhibitMHCexpression in glial cells
(Tontsch and Rott, 1993), the overexpression of MHC genes in the
tumor glia could be the consequence of neuronal damage leading
to alteration of neuroglial contacts accompanied by the difﬁculty
for neurites to establish contact with cells placed within the tumor
mass. Alternatively, tumor astrocytes could become APC-like cells
and thus upregulate their MHC II class expression as suggested
earlier (Vidovic et al., 1990; Nair et al., 2008).
Among the upregulated genes, many growth factors (GFs) are
comprised (Table 2; Table S1 in Supplementary Material). Inter-
estingly, while GFs such as TGFBI, CTGF, VEGF, HBEGF, ERBB2,
platelet derived GFs, insulin like GFs turned out to be overex-
pressed, ﬁbroblast GFs, and their receptors were downregulated.
This conﬁrmed the accuracy of our short-term culture system, rul-
ingout any contaminationbymesenchymal cells. Thederegulation
of genes involved in proliferation and survival also involved cell
cycle regulating genes, such as CDKN1A and CDKN2A. CDKN1A
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Table 3 | Statistically significant biological processes, associated to the downregulated genes only, represented by DE GO terms in our cohort of
glioma samples.
Biological processes GO terms Representative genes Fold change
Neuronal phenotype GO:0019226∼ transmission of nerve impulse KCNMA1 (variant 1) −2.82
GO:0007268∼ synaptic transmission SLC1A2 −2.84
GO:0030182∼neuron differentiation SCN2B −3.01
GO:0031644∼ regulation of neurological system process SCN4B −2.82
GO:0051969∼ regulation of transmission of nerve impulse NEUROD2 −7.74
GO:0050804∼ regulation of synaptic transmission STMN2 −8.49
GO:0048666∼neuron development
Ion transport GO:0030001∼metal ion transport KCNMA1 (variant 1) −2.82
GO:0006811∼ ion transport CACN2D2 −2.27
GO:0006812∼ cation transport ATP1B1 −4.60
SCN2B −3.01
SCN4B −2.82
SLC30A3 −4.08
ATP6V1G2 −4.49
ATP6V0C −2.11
SLC26A1 −3.15
SLCO4A1 −2.45
SLC4A3 −2.52
Some representative genes are reported with the corresponding fold change.
plays also a role in cell protection from apoptosis. Indeed, several
other genes involved in different apoptotic pathways, presented
altered regulation in our samples. For example, members of BCL
families, regulatory genes such asMYC,STAT1, andNOTCH2 were
all overexpressed in our tumor samples.
Moreover, many genes related to the extracellular matrix
(ECM) turned out to be overexpressed in our samples. Among
them, the matrix metalloproteinase (MPPs) MMP9 (6.35, as
reported in Table 2; Table S1 in Supplementary Material) was
highly overexpressed. MMPs upregulation followed the overex-
pression of genes that encode for ECM constituents such as
collagens and ﬁbronectin.
Signiﬁcant downregulation of genes encoding neuronal phe-
notype and ion channels and transporters was apparent in the
pediatric glioma cohort we studied. An overall downregulation of
genes belonging to the “neuronal phenotype” could be expected,
since we compared glial origin tumors with normal brain tissue.
Nevertheless, the deregulation of ion channels and transporters
merits more attention. In particular, it is interesting to note that
most of the downregulated ion channel genes were voltage-gated
potassium and calcium channels. This would suggest deregulation
of glial cell excitability, as previously indicated (Verkhratsky and
Steinhäuser, 2000; Sontheimer, 2008). Only two potassium chan-
nel encoding genes were upregulated, KCNQ1 (Barhanin et al.,
1996) and KCNMA1, encoding the large conductance calcium-
activated potassium channel, KCa1.1. KCa1.1 was upregulated in
various type of tumors, mainly of glial origin (D’Amico et al.,
2012). In the present cohort of pediatric gliomas, only the vari-
ant 2 isoform was upregulated, while the variant 1 isoform
was downregulated. Interestingly, also CACNA2D2, encoding a
calcium channel, was found to be downregulated, in agreement
with Carboni et al. (2003) who identiﬁed CACNA2D2 as a puta-
tive tumor suppressor gene. Finally, the alteration in the expression
level of SCN2B and SCN4B, encoding two sodium channel sub-
unit beta, further stresses the relevance of sodium channels in
gliomas, as recently reported by Joshi et al. (2011). Normal expres-
sion of K+ channels in astrocytes maintains an hyperpolarized
potential which regulates buffering of extracellular K+, pH, and
glutamate (Djukic et al., 2007; Olsen and Sontheimer, 2008).
Our results show that generalized downregulation of K+ chan-
nels occurs in gliomas, in agreement with previous studies on
speciﬁc channel types (e.g., Olsen and Sontheimer, 2008). The
ensuing alteration of the peritumor space composition is likely
enhanced by the concomitant decrease in the expression of elec-
trogenic glutamate transporters (De Groot and Sontheimer, 2011)
and several transporters implicated in pH regulation, such as the
sodium bicarbonate cotransporters (e.g., Table S5 in Supplemen-
tary Material). These effects may contribute to explain the prone-
ness to epileptic seizure development displayed by LGG patients,
as higher extracellular K+, lower pH, and increased glutamate lev-
els tend to produce neuronal hyperexcitability (Buckingham et al.,
2011).
While downregulation of ion channels may decrease the func-
tioning of glial cells (Verkhratsky and Steinhäuser, 2000), dereg-
ulation of gene encoding transporters might have more com-
plex consequences, contributing to multidrug resistance (Car-
boni et al., 2003; Lee et al., 2005; Chen et al., 2006), and/or
enhanced cytotoxicity (Wakaumi et al., 2005; Blair et al., 2011).
Moreover, the downregulation of genes encoding ion trans-
porters, such as V-ATPase genes and SLC4A3 and SLC26A1 could
strongly alter the pH homeostasis (Casey et al., 2009). Inter-
estingly, the genes encoding for the SLC and ABC transporters
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FIGURE 3 | Heatmap of DE genes associated to transporters and ion
channels, performed, and plotted using “heatmap.2” function in R.
Samples and genes (columns and rows respectively) are reordered on the
basis of the average value of gene expression (log 2 ratio), and give rise to
groups of genes and samples with similar average expression levels,
according to the color key on the top.
were almost equally distributed between the up and the down-
regulated genes, whereas the ANXAs were upregulated and the
ATPases were downregulated (except for the ATP6V0E transcript).
The gene encoding ABCC6, which is involved in multidrug resis-
tance, is one of the most strongly upregulated genes. Another
transporter that merit attention is SLC1A2. SLC1A2 expression
tends to decrease glioma cell proliferation (Krona, 2006), and we
assume its downregulation could contribute to increase prolif-
eration in our cohort of samples. Moreover, because SCL1A2 is
the main responsible for clearing extracellular glutamate dur-
ing excitatory synaptic activation in the central nervous sys-
tem, downregulation of SLC1A2 may be a further contributor
to seizure development (Simantov et al., 1999), as discussed
above.
On the whole, determining the GEPs of individual patients
could signiﬁcantly affect the available therapeutic choices.
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Table S1 | Gene differentially expressed (DE) in gliomas compared to
normal brain. About 2284 DE genes identiﬁed by One Sample t -test with a
p-value<0.01, fold change ≥4, and Bonferroni correction.
Table S2 | Functional annotation analyses (FAA) from all DE genes. FAA
performed using NIH-DAVID software (version 6.7, http://david.abcc.ncifcrf.gov/)
on all the DE genes reported in Table S1 in Supplementary Material. We used
the parameter GOTERM_BP_FAT, with the signiﬁcance p-value threshold set
<0.01, with Bonferroni correction.
Table S3 | Functional annotation analysis from differentially overexpressed
genes. FAA performed using NIH-DAVID software (version 6.7,
http://david.abcc.ncifcrf.gov/) on the differentially overexpressed genes reported
in Table S1 in Supplementary Material. We used the parameter
GOTERM_BP_FAT, with the signiﬁcance p-value threshold set <0.01, with
Bonferroni correction.
Table S4 | Functional annotation analysis from differentially
underexpressed genes. FAA performed using NIH-DAVID software (version 6.7,
http://david.abcc.ncifcrf.gov/) on the differentially underexpressed genes
reported in Table S1 in Supplementary Material. We used the parameter
GOTERM_BP_FAT, with the signiﬁcance p-value threshold set <0.01, with
Bonferroni correction.
Table S5 | Differentially expressed genes associated to ion channels and
transporters. Sixty-seven DE genes, associated to ion channels and
transporters, identiﬁed by One Sample t -test with a p-value<0.01, fold change
≥4, and Bonferroni correction.
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